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Background: In the CORRECT phase III trial (NCT01103323), the multikinase
inhibitor REG significantly improved overall survival (OS) and PFS vs placebo in
patients with mCRC who had disease progression after other standard therapies
(HR for OS: 0.77; 1-sided p = 0.0052; Grothey 2013). A post-hoc exploratory subgroup
analysis was conducted to evaluate patients in the REG treatment group who had a PFS
longer than 4 months (long-PFS) defined as patients who progressed, died, or
discontinued treatment for other reasons after 4 months.
Methods: Of the505 patients randomized to REG in CORRECT, 98 (19.4%) were
classified as having a long-PFS benefit. Baseline characteristics, safety, and dosing
parameters were analyzed descriptively.
Results: The long-PFS subpopulation was representative of the overall study
population (Table). Long-PFS patients received a median of 6 cycles of REG (1-12),
92% received ≥5 cycles, and 20% had > 8 cycles. Overall 34% of patients had dose
reductions and 87% had dose interruptions. The actual mean daily dose was 139 mg
and the mean percent of the planned dose was 81%. Adverse events (AE) of any
grade were experienced by all long-PFS patients, and the most common grade ≥3
AEs were hand-foot skin reaction (20%), hypertension (17%), diarrhea (17%), and
fatigue (16%).
Conclusions: A subset of 98 (19.4%) patients treated with REG in the
CORRECT study had a PFS > 4 months, confirming the clinical benefit and
tolerability of REG as a treatment option for patients with mCRC. Prospective
validation of these findings in conjunction with biomarker analysis from real-life
clinical experience is needed.
Clinical trial information: NCT01103323
Table: E13
Baseline characteristics of all REG-treated patients and the long-PFS subgroup
in CORRECT.
All patients
(n=505)
Long-PFS
(n=98)
Median age, yrs (range) 61 (22–82) 61 (34–82)
ECOG PS, % 0
1
52
48
63
37
Primary tumor, % Colon
Rectum
64
30
52
37
Tumor sites, % 1
2
3
19
36
27
30
38
16
KRAS status, % Mutant
Wild-type
54
41
47
44
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